Evaluation of flurbiprofen axetil with fentanyl for postoperative patient-controlled intravenous analgesia in patients underwent resection of esophageal carcinoma

Objective To evaluate the efficacy and safety of flurbiprofen axetil combined with fentanyl for postoperative patient-controlled intravenous analgesia(PCIA)in patients underwent resection of esophageal carcinoma.Methods Sixty ASA class Ⅰ or Ⅱ patients were divided equally and randomly into three groups of fentanyl 1.0 mg+droperidol 2.5 mg(group A),fentanyl 0.5 mg+flurbiprofen axetil 100 mg+droperidol 2.5 mg(group B) and fentanyl 0.5 mg+flurbiprofen axetil 50 mg+droperidol 2.5 mg and additionally injected with intravenous flurbiprofen axtil 50 mg prior to the surgery(group C).The VAS,Ramsay sedation scale,PCIA pressing times and the adverse effects were recorded at 1,2,4,8,12,24,36,48 h after surgery.Results Patients in the three groups did not show significant difference in the VAS and PCIA pressing times.Ramsay sedation scale,the incidence rate of adverse events such as nausea and vomiting in group A were significantly higher than those in group B and C.Conclusion Co-administration of flurbiprofen axetil with fentanyl by PCIA offers overall favorable analgesic responses as well as the reduction of fentanyl consumption during PCIA in the patients following esophageal carcinoma surgery.